2023年9月11日 · BA.2和BF.7变异株感染者潜伏期M(Q 1 ，Q 3)分别为3.00(3.00，4.00)d和3.00(2.00，3.25)d。lognormal分布的拟合效果最佳。多因素方差分析结果显示，不同类型 …

由严重急性呼吸综合征2型冠状病毒 (SARSCoV-2)引起的2019年冠状病毒病 (COVID-19)大流行，由于omicron（奥密克戎）变种及其后代亚变种的出现，持续爆发。 尽管BA.5子变种目前在 …

BA.2亚型毒株是 英国 发现的 奥密克戎 毒株新变种，相较BA.1，变异毒株BA.2的传播性更强。 [1] [11] 2022年1月21日，英国卫生安全局表示，正在调查奥密克戎毒株新变种BA.2亚型毒株在英 …

2023年3月1日 · The evolutionary analysis of BA.5.2 variant shows that the variant is composed of two sub-variants, named BA.5.2.48 and BA.5.2.49 by PANGO, respectively. This variant may …

Our results showed that naive and breakthrough infections with BA.2, BA.5 and BF.7 variants induced limited cross-neutralizing responses, especially for the BQ.1.1 and XBB related …

2023年8月26日 · Immune escape of BA.2.75, BQ, XBB and XBF variants was also evident in bivalently boosted individuals, however, cross-neutralization was improved for those with …

2023年9月10日 · Objective: To understand the incubation periods of infections of Omicron variants BA.2 and BF.7 in two COVID-19 epidemics and related factors in Beijing and provide …

2023年3月15日 · Recently, a number of new Omicron subvariants related to BA.4/5 and BA.2.75 have emerged and shown remarkable antibody evasion capacities, in particular BF.7, BQ.1, …

Naive and breakthrough infections with BA.2, BA.5 and BF.7 variants provide poor cross protection against XBB related variants J Infect . 2023 Aug;87(2):156-159. doi: …

We investigated the serum neutralization efficacy of Evusheld (cilgavimab and tixagevimab) against SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1, and XBB.1.5. A …